Everolimus can be combined with certain targeted agents or hormonal therapies, but drug-drug interactions are common, especially with drugs metabolized by CYP3A4. Your oncologist will review all concurrent medications to adjust doses or select compatible treatments.
Yes. For optimal absorption, take the pill on an empty stomach-at least 1 hour before eating or 2 hours after a meal. Water is the preferred vehicle.
Mouth sores are a frequent side effect. Rinse gently with a salt-water solution several times daily, avoid spicy or acidic foods, and discuss topical steroids or protective mouthwashes with your clinician.
Travel is generally safe, but bring a copy of your prescription and a letter from your doctor for customs checks. Keep tablets in their original container, and maintain your dosing schedule across time zones.
Everolimus shares the same mechanism as temsirolimus but differs in formulation (oral pill vs. intravenous infusion) and approved indications. Dosing schedules and side-effect profiles vary accordingly.
Some supplements, particularly St. John’s wort, can induce CYP3A4 and reduce everolimus levels. Always disclose any over-the-counter products to your healthcare team before use.
Everolimus may raise blood glucose levels. Monitor glucose more frequently, adjust diabetes medications as needed, and report persistent hyperglycemia to your provider.
Treatment duration is individualized; many patients continue until disease progression or unacceptable toxicity occurs. Regular assessments guide continuation decisions.
Afinitor tablets are round, bicolored (white and pink for the 5 mg strength, white and blue for the 10 mg strength), and bear the imprint “EVEROLIMUS 5 MG” or “EVEROLIMUS 10 MG” respectively.
Hong Kong’s public health system may subsidize certain oncology drugs, but eligibility varies. Patients should consult the Hospital Authority or their pharmacist for information on assistance schemes.
Afinitor contains everolimus as its active component. Everolimus is an oral mTOR (mechanistic target of rapamycin) inhibitor used as part of oncology support therapy. The medication is supplied as a pill in two strengths-5 mg and 10 mg. In Hong Kong, Afinium is a prescription-only (Rx) drug regulated by the Department of Health under the Medicines and Poisons Ordinance.
Everolimus belongs to the rapamycin-derived class of targeted therapies. It binds to the intracellular protein FKBP-12, forming a complex that blocks the mTORC1 signaling pathway. By inhibiting mTORC1, everolimus reduces cell proliferation, angiogenesis, and protein synthesis-processes that many cancer cells rely on for growth and survival. The drug’s effect begins within hours of the first dose, reaches steady-state concentrations after about a week of daily dosing, and its pharmacologic activity persists for the dosing interval.
Afinitor is approved by major regulatory agencies for several oncology indications, including:
These approvals are reflected in the product label used in Hong Kong and align with FDA and EMA indications.
Evidence-Based Off-Label Uses
All off-label applications require individualized risk assessment and close monitoring by an oncology specialist.
This article provides educational information about Afinitor and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
